Savant Capital’s 10x Genomics TXG Stock Holding History

Savant Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40,247	Closed	-$578K	–	1409
2024 Q4	$578K	Buy	40,247 +16,480	+69%	+$260K	﹤0.01%	833
2024 Q3	$537K	Buy	+23,767	New	+$491K	﹤0.01%	844

Other funds holding TXG

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Savant Capital's TXG Position: Q1 2025 in Review

Savant Capital sold out of 10x Genomics (TXG) in Q1 2025, closing a stake of 40,247 shares — an estimated $578K sold.

Savant Capital first reported a position in TXG in Q3 2024 and held it in 2 quarters. The position peaked at $578K in Q4 2024. 274 funds tracked by Wall St. Rank hold TXG as of Q1 2025.

Savant Capital reported no remaining 10x Genomics position as of Q1 2025 after selling out during the quarter.
Savant Capital sold 40,247 10x Genomics shares in Q1 2025, an estimated $578K.
Savant Capital first reported a position in 10x Genomics in Q3 2024 and held it in 2 quarters.
Savant Capital's 10x Genomics position peaked at $578K in Q4 2024.
274 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.